OUTCOMES OF ELTROMBOPAG TREATMENT AND DEVELOPMENT OF IRON DEFICIENCY IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA IN TURKEY
Open Access
- 17 March 2020
- journal article
- research article
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 37 (3) , 139-144
Abstract
Objective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, or petechiae. The thrombopoietin receptor agonist eltrombopag (EPAG) is a second-line agent used to treat chronic ITP purpura in adults and children. Materials and Methods: The present retrospective study evaluated the efficacy, safety, and side effects of EPAG treatment in pediatric patients with acute refractory and chronic immune thrombocytopenia, particularly focusing on iron-deficiency anemia. Results: The diagnosis was chronic ITP in 89 patients and acute refractory ITP in 16 patients. The mean age of patients was 9.5 +/- 4.5 years (minimum-maximum: 1.2-18 years) at the beginning of EPAG treatment. The overall response rate was 74.3% (n=78). The mean time for platelet count of >= 50x109/L was 11.6 +/- 8 weeks (range: 1-34 weeks). The treatment was stopped for 27 patients (25.7%) at an average of 6.8 +/- 9 months (range: 1-38 months). The reason for discontinuation was lack of response in 18 patients, nonadherence in 4 patients, and hepatotoxicity in 2 patients. Response to treatment continued for an average of 4 months after cessation of EPAG in 3 patients. Conclusion: Results of the current study imply that EPAG is an effective therapeutic option in pediatric patients with acute refractory and chronic ITP. However, patients must be closely monitored for response and side effects during treatment, and especially for iron deficiency.Keywords
This publication has 20 references indexed in Scilit:
- A Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Study to Determine the Effect of Romiplostim on Health‐Related Quality of Life in Children with Primary Immune Thrombocytopenia and Associated Burden in Their ParentsPediatric Blood & Cancer, 2016
- Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trialThe Lancet, 2015
- Quality of life in immune thrombocytopenia following treatmentArchives of Disease in Childhood, 2013
- Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiationBlood, 2012
- A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopeniaBlood, 2011
- Guideline for investigation and management of adults and children presenting with a thrombocytosisBritish Journal of Haematology, 2010
- Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet functionExperimental Hematology, 2009
- Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working groupBlood, 2009
- Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic PurpuraNew England Journal of Medicine, 2007
- Thrombopoietin is not uniquely responsible for thrombocytosis in inflammatory disordersPlatelets, 2007